• New framework needed for estimating the social cost of carbon: Report

    To estimate the social cost of carbon dioxide for use in regulatory impact analyses, the federal government should use a new framework that would strengthen the scientific basis, provide greater transparency, and improve characterization of the uncertainties of the estimates, says a new report by the National Academies of Sciences. The report also identifies a number of near- and longer-term improvements that should be made for calculating the social cost of carbon.

  • St. Jude's cardiac devices vulnerable to hacking: FDA

    The FDA confirmed that St. Jude Medical’s implantable cardiac devices are vulnerable to hacking. Once hackers gain access to the device, they could deplete the battery or administer incorrect pacing or shocks. The devices — pacemakers and defibrillators — are used in heart patients.

  • Lawmakers want to know more about Ricin mix-up

    Members of the Committee on Homeland Security sent a letter on 23 December to FEMA administrator Craig Fugate, demanding answers on how many years had first responders unknowingly trained with toxic Ricin at Anniston’s Center for Domestic Preparedness (CDP). In a three-page letter, members of the committee demanded answers for  twelve questions, addressing the issue of how lethal toxin was used and the agency’s response once it found out about the mix-up.

  • Odds are against a large Zika outbreak in the U.S.

    Is the United States at risk for a large-scale outbreak of Zika or other mosquito-borne disease? While climate conditions in the United States are increasingly favorable to mosquitos, socioeconomic factors such as access to clean water and air conditioning make large-scale outbreaks unlikely, according to new analysis of existing research — but small-scale, localized outbreaks are an ongoing concern.

  • $1.87 million for biothreat vaccine research

    CUBRC, Inc. two weeks ago announced that CUBRC’s Biological and Medical Sciences team, in collaboration with EpiVax, Inc., has received a four-year grant worth $1.87 million from the Defense Threat Reduction Agency (DTRA) within the Department of Defense (DoD). CUBRC, EpiVax, and scientists at the University of Florida will be investigating immune cells from patients that were previously infected with Burkholderia pseudomallei to understand how this bacterium evades the human immune system and use that information to engineer an effective vaccine.

  • Final trial results confirm Ebola vaccine provides high protection against disease

    Since Ebola virus was first identified in 1976, sporadic outbreaks have been reported in Africa. But the 2013-2016 West African Ebola outbreak, which resulted in more than 11,300 deaths, highlighted the need for a vaccine. An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.

  • The new “100% effective” Ebola vaccine owes a debt to the scientists who beat smallpox

    Almost a year after the official end of the Ebola outbreak in West Africa, the final results from one of the only Ebola vaccine trials are now in – and they look very promising. Despite being carried out under some of the most challenging conditions, the trial appears to be an exceptionally well-run study, comprehensive in its nature, and with a very positive result. This surely cements this vaccine as one important tool in controlling outbreaks of Ebola in the future. It also gives us a way to test new vaccines for other viruses that can crop up and take us by surprise, such as Lassa fever virus and Nipah viruses. We just have to hope that scientists have got more vaccines in the pipeline for us to test.

  • Whitefly: a formidable threat to food security

    Researchers have sequenced the genome of the whitefly (Bemisia tabici), an invasive insect responsible for spreading plant viruses worldwide, causing billions of dollars in crop losses each year. The genome study offers many clues to the insect’s remarkable ability to resist pesticides, transmit more than 300 plant viruses, and to feed on at least 1,000 different plant species.

  • Dust Bowl would devastate today’s crops: Study

    A drought on the scale of the legendary Dust Bowl crisis of the 1930s would have similarly destructive effects on U.S. agriculture today, despite technological and agricultural advances, a new study finds. Additionally, warming temperatures could lead to crop losses at the scale of the Dust Bowl, even in normal precipitation years by the mid-twenty first century.

  • Health wearable devices pose new consumer and privacy risks

    Watches, fitness bands, and so-called “smart” clothing, linked to apps and mobile devices, are part of a growing “connected-health” system in the U.S., promising to provide people with more efficient ways to manage their own health. These personal health wearable devices, which are used to monitor heart rates, sleep patterns, calories, and even stress levels, raise new privacy and security risks, according to a new report.

  • New math can help fight viral outbreaks

    HIV … SARS … Ebola … H1N1 … Zika. The list of communicable global health threats seems ever growing, and frequently the limited resources available to fight these diseases must be picked up and redeployed — often haphazardly — as the next new threat emerges. But what if there were ways to wage a more effective war against all communicable diseases, using new combinations of proven complex sociological and statistical mathematic models to tell where an outbreak might occur, how it might spread and how best to fight it?

  • Biological emergences: Incremental progress not enough

    While acknowledging some positive efforts over the past year by the White House and Congress, the bipartisan Blue Ribbon Study Panel on Biodefense says the incremental progress is not enough to defend against biological emergencies, let alone catastrophic events. The report, Biodefense Indicators – One Year Later, Events Outpacing Federal Efforts to Defend the Nation, states that while the biological threat is real and continues to grow, our nation remains woefully under-prepared for dangerous biological incidents.

  • Developing the National Livestock Readiness Program

    The National Agricultural Biosecurity Center has received $331,118 from the Department of Homeland Security through its Basic Ordering Agreement with K-State to develop the National Livestock Readiness Program. The project, with its initial deliverables completed by September 2017, will provide a clearinghouse for planning, training, and knowledge products to help state and local entities prepare for transboundary livestock disease outbreaks.

  • Real-time online epidemic tracking tool relies on open data, collective intelligence

    Until now, disease data and geographic information about the movement of an infection or disease as it evolves and spreads has been locked up in databases that are often out of people’s reach. Researchers have been left to rely on published information in research papers, which may be many months out of date, containing static visuals which show only a small part of the whole disease or infection threat. Now, researchers have developed Microreact, a free, real-time epidemic visualization and tracking platform that has been used to monitor outbreaks of Ebola, Zika, and antibiotic-resistant microbes.

  • Emergent BioSolutions to supply up to $1 billion of anthrax vaccine to the Strategic National Stockpile

    Emergent BioSolutions signed follow-on contract with CDC valued at up to $911 million to supply to the Strategic National Stockpile (SNS) approximately 29.4 million doses of BioThrax through September 2021. BARDA issued notice of intent to separately procure approximately $100 million of BioThrax for the SNS over twenty-four months from contract award, which is expected in 1H 2017. These actions, together with the recently awarded BARDA contract for NuThrax, reflect the U.S. government’s intention to transition the stockpile of anthrax vaccines from BioThrax to NuThrax.